These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 14961215

  • 21. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

  • 22. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
    Gonc EN, Kandemir N.
    Clin Endocrinol (Oxf); 2007 May 01; 66(5):672-7. PubMed ID: 17381489
    [Abstract] [Full Text] [Related]

  • 26. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456].
    Forsblad d'Elia H, Christgau S, Mattsson LA, Saxne T, Ohlsson C, Nordborg E, Carlsten H.
    Arthritis Res Ther; 2004 May 01; 6(5):R457-68. PubMed ID: 15380045
    [Abstract] [Full Text] [Related]

  • 27. Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study.
    Ausmanas MK, Holinka CF, Ling YS, Christiansen C.
    Climacteric; 2007 Aug 01; 10(4):306-13. PubMed ID: 17653957
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF, Margioris AN, Dretakis KE, Trovas G, Zoras U, Lyritis G, Dretakis EK, Stergiopoulos K.
    Maturitas; 2004 Mar 15; 47(3):185-93. PubMed ID: 15036488
    [Abstract] [Full Text] [Related]

  • 31. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR.
    Maturitas; 2008 Jan 20; 59(1):2-6. PubMed ID: 18063490
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK, Pietropolli A, Ticconi C, Gravotta E, De Martino MU, Fabbri A, Piccione E.
    J Obstet Gynaecol Res; 2009 Feb 20; 35(1):152-9. PubMed ID: 19215563
    [Abstract] [Full Text] [Related]

  • 34. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis.
    Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C.
    J Bone Miner Res; 1997 Apr 20; 12(4):624-31. PubMed ID: 9101374
    [Abstract] [Full Text] [Related]

  • 35. Biomarkers of bone health and osteoporosis risk.
    Eastell R, Hannon RA.
    Proc Nutr Soc; 2008 May 20; 67(2):157-62. PubMed ID: 18412989
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 May 20; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.